|
|
Updates to Managing COVID-19 guideline
The following new recommendations have been added to our Managing COVID-19 guideline (NG191):
We’ve also updated the following existing recommendations:
We are continuously updating this guideline to incorporate the latest evidence and keep abreast of new developments in diagnosing and treating COVID-19. We’ll highlight recent updates in this monthly email communication, or you can keep up-to-date on the latest live changes through our website.
|
|
NICE is transforming: our strategic plan 2021 to 2026
Watch a short animation to understand the focus of our new 5-year strategy and how we aim to meet the evolving needs of the health and care system. We’re going to be creating easier-to-use ‘living’ guidelines based on the latest evidence and addressing your most important questions.
|
|
Our draft guidance recommends several treatment options for around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies. Adalimumab, etanercept and infliximab, taken with methotrexate have been recommended for use within the NHS. Adalimumab and etanercept can also be used as monotherapy when methotrexate is contraindicated or not tolerated.
|
In our latest guideline, we recommend that shared decision making should be part of everyday practice across all healthcare settings. The guideline sets out ways for healthcare professionals to work with people using services to make decisions about their treatment and care. We recommend use of posters and patient decision aid leaflets to help raise awareness of this process.
|
|
This new guideline is the first by NICE to address acne vulgaris. It offers recommendations on pharmacological and photodynamic therapies and emphasises the importance of supporting the mental health of individuals who are experiencing significant psychological distress as a result of their condition.
|
This draft guideline makes recommendations on e-cigarettes and the use of voucher incentives to encourage pregnant women to quit. Tobacco: preventing uptake, promoting quitting and treating dependence consolidates and updates 8 previous guidelines on smoking. We’re consulting on the draft recommendations until Friday 6 August.
|
|
Clinical knowledge summaries
|
|
|
We’ve updated the following clinical knowledge summary (CKS) topics since the start of June:
- Atrial fibrillation, to align the topic with our updated guideline on the condition (NG196). This includes the recommendation to use the ORBIT bleeding risk assessment tool when considering starting anticoagulation in people with atrial fibrillation, and that a direct oral anticoagulant should be used first-line in people considered to be at risk of stroke.
- Cervical screening, Cervical cancer and HPV, Shingles, Hepatitis B, Glandular fever, Chest infections, Platelets, Seborrhoeic dermatitis, Psoriasis, Diarrhoea, Candida, Chronic kidney disease, HIV infection and AIDs to highlight HIV indicator conditions in line with the British HIV Association, British Association for Sexual Health and HIV, and British Infection Association, adult HIV testing guidelines.
- Hypothyroidism to explain new prescribing advice for patients who experience symptoms on switching between different levothyroxine products. This aligns with advice from the Medicines and Healthcare products Regulatory Agency.
- Conjunctivitis – infective. We've updated a recommendation explaining that the use of chloramphenicol eyes drops is contraindicated in children aged under 2 years.
Our CKS provide primary care practitioners with a readily accessible summary of the evidence base and best practice guidance for over 370 topics. These cover 1,000 clinical presentations or patient scenarios, free to access in the UK.
|
|
Implementing guidance on long-acting reversible contraception
Nicola Thorley is a consultant in HIV and sexual health. She’s also a former NICE fellow. During her fellowship, Nicola used our guidance on long-acting reversible contraception to develop the Umbrella sexual health service in Birmingham and Solihull to:
- reduce pressure on secondary care by providing services within primary care
- set up data monitoring systems for long-acting reversible contraceptive activity in primary care
- train pharmacists to deliver a range of sexual health services
- improve signposting to pharmacists and GPs through the Umbrella sexual health service website
- encourage signposting from sexual health clinics to pharmacies.
There are now around 157 Umbrella pharmacies across the region expanding the scope of service delivery.
NICE fellows are senior influential leaders who act as ambassadors for NICE’s work for 3 years. They use their strong networks to promote the work of NICE at a regional and national level.
|
|
Hear Glue Ear app delivers NICE ear care pathway
Cambridgeshire Community Services NHS Trust developed the Hear Glue Ear app to support children and their families. The free app:
- delivers glue ear information, advice, books, games and songs in a format that children like and recognise
- covers specific recommendations from our guideline on surgical treatment of children under 12 with otitis media with effusion (also called glue ear)
- helps to keep children from falling behind with speech and language, listening skills and learning
- provides parents with up to date and evidence-based information and behavioural strategies.
During the project, 73% of the families involved downloaded the app. They said that it helped them become more engaged with the glue ear care pathway. They also felt more in control of helping their child between appointments. The app has won both the Leading Health Care award and Children’s app of the year 2019 award at the UK App Awards.
This project is one of many implementation case studies contained in our shared learning collection.
|
|
Siân Phipps, lay member on our shared decision making guideline committee, explains why our new guideline will help transform people’s experiences of health and social care.
|
|
|
Jeanette Kusel, director of scientific advice at NICE, explains how we are working to improve patient access to the best artificial intelligence-driven digital health technologies.
|
|
|
Share your views about NICE: take a short survey
We would like to invite you to share your views and experience of engaging with NICE through a new research project. Your feedback will be used to help evaluate and improve how we operate, our work and resources, and our strategic ambitions.
Closing date: Friday 16 July 2021.
|
|
Comment on a consultation
Our current consultations include:
|
|
Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
|
|
Join a committee
We’re looking for members and topic experts to join our:
|
|
Observe a meeting
Due to the pandemic, we're holding all our public meetings virtually. You'll need to register in advance to join.
Upcoming public meeting:
- Tuesday 13 July 2021 – Quality standards advisory committee
Registration closes Tuesday 6 July 2021.
Agenda and register
|
|
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
|
|
The chair of our interventional procedures advisory committee, Professor Tom Clutton-Brock, has been awarded an MBE for services to the NHS during the COVID-19 pandemic. Professor Clutton-Brock and the Medical Devices Testing and Evaluation Centre team, played a vital role in developing and testing ventilator prototypes. Devices approved by the team are now in use at hospitals across several countries.
|
|
|
|
|
|
|